Categories Technology

Uber, Grab merger happened without anti-trust approval, faces penalty

Cab-hailing service Uber Technologies and its Singaporean counterpart Grab may face hefty fines or even a breakdown of their merger, as the deal was allegedly made without obtaining approval from anti-trust authorities. The Asian country’s regulatory watchdog, Competition and Consumer Commission of Singapore (CCCS), today claimed that neither of the companies notified them on the merger, despite clear indications that it would hurt healthy competition in the country.

This will be the first instance of CCCS slapping a fine on a merger. The authority has also sought suggestions and feedback on the same from the public.

An uber self driving car on road
Image courtesy: Dillu, Wikipedia

RELATED: Uber and its Chinese rival Didi to race in Australia

CCCS claims that the deal has led to an increase in taxi fares, and feels it would lead to a decline in innovation in the sector. It is currently up to the authority to decide whether to stick to a fine or nullify the deal as such.

In its second-largest withdrawal from an Asian market, Uber had sold its Southeast Asia to Grab in March. In return, the US company received 27.5% stake in Grab as well as a spot for CEO Dara Khosrowshahi in Grab’s board.

The regulatory authority said, “CCCS may require the parties to unwind the transaction unless the aforesaid public consultation confirms that any of the proposed remedies, or any further remedies, are sufficient to address the identified competition concerns, and are implementable in practice.”

RELATED: Uber in talks with rival Waymo over self-driving partnership

CCCS has come up with a few remedies to make sure competition is not hurt. These include removal of exclusivity that Grab currently holds with other taxi services, besides Uber selling its car rental unit to a Grab competitor. The companies have been given 15 days to draft their remedies and submit to the regulator.

RELATED: Uber and Lyft may soon clash over e-scooters

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top